SwedenBIO at European Parliament Outreach Event in Strasbourg, Oct 20th

The event, hosted by Swedish EPP MEP Christofer Fjellner, highlighted the increasingly influential role played by patients in managing their own care and recovery.
So far, more than 350 million patients have benefitted from medicines manufactured through biotechnology and gene technology to treat or prevent heart attacks, strokes, multiple sclerosis, breast cancer, cystic fibrosis, leukemia, hepatitis, diabetes and other diseases. In addition, an estimated 50% of all new medicines will originate from biotechnologies.
Christofer Fjellner commented:
"Today's session has helped raise awareness of the urgent need to update and modernize current legislation on information about medicines. It's evident that we need better access to information about medicines to empower patients all over Europe. To achieve this we need a broad commitment from all European institutions."

To pressrelease by Europabio